• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

The Diabetes Series 2008: Experts Speak About Developing Diabetes Therapeutics

Posted on: Monday, 25 February 2008, 09:01 CST

SAN DIEGO, Feb. 25 /PRNewswire/ -- Speid & Associates, a San Diego-based regulatory affairs and drug development consultancy, is hosting a six session Webinar series on diabetes and related metabolic diseases during the months of March and April. Speakers will include former Food and Drug Administration officials Dr. Alexander Fleming and Dr. Ray Lipicky, as well as a distinguished list of other guest speakers and panelists.

Researchers and companies involved in diabetes therapeutic development are finding a complex array of possible targets across diabetes (both type 1, type 2), the metabolic syndrome, and the complications and causes of diabetes. This translates into a complex pathway for therapeutic development and registration with many potential pitfalls along the way. The webinar series will promote discussion on the inter-related issues of diabetes/metabolic therapeutic development and registration.

Dr. Speid said, "I am delighted that the series will feature such a stellar list of speakers, to address these important topics and issues." Dr. Alexander Fleming, ex-FDA (formerly headed diabetes drug review) said, "There is no more active and controversial therapeutic development area than for diabetes drugs. I look forward to discussing the implications of the ACCORD trial and a number of other timely topics."

For many years, Dr. Ray Lipicky headed FDA's Division of Cardiorenal Drug Products. Among his many drug approvals was the first and essentially only approval of treatments for a diabetic complication. The participation of Drs. Lipicky and Fleming in this series mirrors the convergence of cardiovascular and metabolic therapeutics at multiple levels -- pathophysiology, drug targets, trial design, and clinical disciplines.

Speid & Associates, Inc. is a regulatory affairs and drug development consultancy based in San Diego, Calif. The firm, founded in 2004 by Dr. Lorna Speid, Ph.D., assists life science companies at various stages in the drug development process. Speid's services, which vary from building global regulatory strategies to conducting due diligence for possible drug acquisitions, save large and small pharmaceutical firms from costly mistakes. Dr. Speid began her career as a pharmacist in the UK, after which she completed a Ph.D. at the Centre for Medicines Research International, into the Safety Assessment of Medicines, Pre and Post Marketing. Before forming her own consultancy, Dr. Speid worked for Sanofi Winthrop in the UK, Ciba Geigy and Novartis in Switzerland (HQ). Dr. Speid also worked for a number of small pharmaceutical companies, two of them at the Vice President level. For more information, see http://www.sndtm.com/.

Further information regarding the webinar series is available at: http://www.sndtm.com/webinar.html as well as sign up instructions.

Telephone 858 793 1295. Email lspeid@sndtm.com.

Speid & Associates, Inc.

CONTACT: Dr. Lorna Speid, Speid & Associates, Inc., +1-858-793-1295,Cell: +1-858-531-6640

Web site: http://www.sndtm.com/http://www.sndtm.com/webinar.html

Source: PRNewswire

More News in this Category